1. 66PAdapting a prescreening program to match molecular alterations in over 5, 000 patients' tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years. (16th September 2018) Authors: Aguilar, S; Vivancos, A; Nuciforo, P; Viaplana, C; Ruiz-Pace, F; Sanchez, E; Rodon, J; Tabernero, J; Garralda, E; Dienstmann, R Journal: Annals of oncology Issue: Volume 29:Number 6(2018)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (23rd March 2019) Authors: Veeraraghavan, J; Angelis, C De; Mao, R; Wang, T; Herrera, S; Pavlick, A C; Contreras, A; Nuciforo, P; Mayer, I A; Forero, A; Nanda, R; Goetz, M P; Chang, J C; Wolff, A C; Krop, I E; Fuqua, S A W; Prat, A; Hilsenbeck, S G; Weigelt, B; Reis-Filho, J S Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. (12th October 2017) Authors: Nuciforo, P; Pascual, T; Cortés, J; Llombart-Cussac, A; Fasani, R; Paré, L; Oliveira, M; Galvan, P; Martínez, N; Bermejo, B; Vidal, M; Pernas, S; López, R; Muñoz, M; Garau, I; Manso, L; Alarcón, J; Martínez, E; Rodrik-Outmezguine, V; Brase, J C Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cancer stem cell theory: pathologists' considerations and ruminations about wasting time and wrong evaluations. Issue 7 (25th June 2004) Authors: Nuciforo, P; Fraggetta, F Journal: Journal of clinical pathology Issue: Volume 57:Issue 7(2004) Page Start: 782 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (30th April 2018) Authors: Mattos-Arruda, L De; Weigelt, B; Cortes, J; Won, H H; Ng, C K Y; Nuciforo, P; Bidard, F -C; Aura, C; Saura, C; Peg, V; Piscuoglio, S; Oliveira, M; Smolders, Y; Patel, P; Norton, L; Tabernero, J; Berger, M F; Seoane, J; Reis-Filho, J S Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Early evolutionary divergence between papillary and anaplastic thyroid cancers. (10th April 2018) Authors: Capdevila, J; Mayor, R; Mancuso, F M; Iglesias, C; Caratù, G; Matos, I; Zafón, C; Hernando, J; Petit, A; Nuciforo, P; Cameselle-Teijeiro, J M; Álvarez, C; Recio, J A; Tabernero, J; Matias-Guiu, X; Vivancos, A; Seoane, J Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Early evolutionary divergence between papillary and anaplastic thyroid cancers. (13th August 2019) Authors: Capdevila, J; Mayor, R; Mancuso, F M; Iglesias, C; Caratú, G; Matos, I; Zafón, C; Hernando, J; Petit, A; Nuciforo, P; Cameselle-Teijeiro, J M; Álvarez, C V; Recio, J A; Tabernero, J; Matias-Guiu, X; Vivancos, A; Seoane, J Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1843 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. (30th May 2019) Authors: Oliveira, M; Saura, C; Nuciforo, P; Calvo, I; Andersen, J; Passos-Coelho, J L; Gil Gil, M; Bermejo, B; Patt, D A; Ciruelos, E; de la Peña, L; Xu, N; Wongchenko, M; Shi, Z; Singel, S M; Isakoff, S J Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1289 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (26th April 2018) Authors: Shi, W; Jiang, T; Nuciforo, P; Hatzis, C; Holmes, E; Harbeck, N; Sotiriou, C; Peña, L; Loi, S; Rosa, D D; Chia, S; Wardley, A; Ueno, T; Rossari, J; Eidtmann, H; Armour, A; Piccart-Gebhart, M; Rimm, D L; Baselga, J; Pusztai, L Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (9th January 2019) Authors: Shi, W; Jiang, T; Nuciforo, P; Hatzis, C; Holmes, E; Harbeck, N; Sotiriou, C; Peña, L; Loi, S; Rosa, D D; Chia, S; Wardley, A; Ueno, T; Rossari, J; Eidtmann, H; Armour, A; Piccart-Gebhart, M; Rimm, D L; Baselga, J; Pusztai, L Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 1018 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗